India MedTech Market: Underestimated, Misread, and Still Worth Entering

India’s medical device market is currently valued at approximately USD 10–12 billion, roughly one-fifth the size of China’s. That comparison alone tends to undersell it. With sustained annual growth of 8–10% across the overall market—and higher rates in select categories—India’s strategic value lies not in its current scale but in the combination of trajectory and structural demand drivers: 1.4 billion people, a rapidly expanding middle class, rising chronic disease burden, and substantial gaps in healthcare infrastructure that will take decades to close.

Unlike the fragmented archipelago markets of Southeast Asia, India operates under a single national regulatory framework, with English as the common language of commerce and a relatively mature import and distribution infrastructure. For manufacturers that can establish a meaningful presence, scale economics are real: once the market is working, marginal costs fall sharply.

Policy Reality vs. Buyer Reality

The claim that “India is unfriendly to foreign companies” circulates widely in the MedTech industry. It is not entirely without basis, but it conflates two distinct things: government policy and buyer behavior.

At the policy level, India has genuine protectionist tendencies. The Production Linked Incentive (PLI) scheme, introduced in 2020, explicitly encourages domestic manufacturing and aims to reduce import dependence. Import tariffs on medical devices range from 12% to 20% for certain product categories, and registration requirements have tightened progressively since 2022.

At the buyer level, the picture is different. Procurement teams at public hospitals, government tender offices, and private hospital groups do not systematically exclude Chinese brands. What they do consistently require is reliable after-sales service, local technical support, accessible spare parts, and clinical training. These are the same standards they apply to all foreign suppliers. The distinction matters: protectionist policy and buyer preference are separate variables, and conflating them leads to inaccurate market assessments.

Three Segments With Distinct Entry Logic

India is not a single market. Its complexity is largely a function of dramatic differences between market segments, and understanding those differences is the prerequisite for any realistic entry strategy.

Public Healthcare System: High Volume, Long Cycles, Politically Driven

India’s public hospital network handles approximately 60% of outpatient and inpatient volume nationally, serving predominantly low- and middle-income patients. Government procurement at this level is substantial but highly political: large equipment tenders are typically managed at the state level, with procurement cycles measured in years, payment terms that can extend further, and intense price competition. Public sector procurement is not an appropriate beachhead for most foreign entrants—but once a market base is established, it can become a meaningful volume channel.

Private Hospital Groups: Higher Standards, Scalable, Margin-Positive

The large private hospital chains—Fortis, Apollo, Manipal, Max Healthcare, and others—represent the most accessible entry point for Chinese mid-to-premium MedTech brands. These groups operate dozens to hundreds of facilities under centralized procurement governance. Clinical standards are high, management teams are internationally educated, and purchasing decisions reflect genuine product evaluation rather than pure price sensitivity. Critically, a single successful engagement with a large private group can influence multiple hospitals simultaneously, accelerating both revenue and clinical reference development.

Tier-2 and Tier-3 Markets: Large Demand, High Service Cost

India’s secondary cities and rural areas represent substantial latent demand, increasingly activated by the government’s “Healthy India” infrastructure program. But coverage economics are punishing. India’s logistics infrastructure—particularly in central and eastern states—is significantly less developed than China’s, making after-sales support and technical service difficult and expensive. This is why Indian distribution typically operates across multiple tiers: national distributor → regional wholesaler → state agent → local dealer. Each layer absorbs a portion of coverage cost and customer relationship management. Products with high service complexity or consumable dependency face meaningful constraints in these markets.

Understanding the Multi-Tier Distribution Structure

Many Chinese companies interpret India’s multi-tier channel as a margin problem to be engineered around. This is a misreading. The layered distribution structure is an adaptive response to market fragmentation: 28 states with distinct languages, commercial ecosystems, procurement rules, and sometimes divergent regulatory enforcement practices. No national distributor can efficiently serve all of these market units directly. The layers exist because they perform real functions.

The correct question is not how to eliminate tiers, but how to design the interest structure across tiers so that each level has adequate incentive to perform its role. Poorly structured distributor economics—whether at the national or regional level—reliably produce poor market performance. This dynamic is not unique to India, but it is especially pronounced there given how dependent downstream performance is on local relationships and local language.

The wealth distribution gap across India also creates a product strategy imperative. The same product cannot be positioned identically at a Mumbai private hospital and a district hospital in Bihar. A Good-Better-Best product architecture is not a luxury in India—it is a practical necessity for companies that want to cover more than one segment.

Registration: A Clear Path With Strategic Implications

India’s medical device registration is administered by the Central Drugs Standard Control Organisation (CDSCO), under a four-class risk framework (A through D). Class A and B devices—lower risk—can be registered on the basis of ISO 13485 certification and existing CE or FDA approval, typically within one to two years. Class C and D devices face higher requirements, including in some cases local clinical data.

Since 2024, India has tightened import registration requirements, mandating manufacturer authorization registration with CDSCO for importers and applying stricter review to new product categories. Companies that did not anticipate these changes have experienced shipment delays and sales disruptions.

The more consequential issue, however, is the relationship between registration and channel strategy. Indian registration typically requires a local License Holder—either the importer or a locally incorporated subsidiary. This means registration ownership and distribution relationships are structurally linked. If a product’s registration is held by a distributor rather than the manufacturer or manufacturer’s local entity, changing that distributor later carries significant legal and commercial friction.

Registration in India is not only a compliance question—it is a channel control question. Who holds the registration determines who holds market leverage. This needs to be resolved before the first distributor agreement is signed, not after.

The Invisible Barrier: Visa Constraints and the Knowledge Gap

Since 2020, Chinese business nationals have faced severe practical difficulty obtaining visas to India. This is not a minor inconvenience—it has created a structural information gap that affects the quality of strategic decision-making across the industry. Business development managers nominally responsible for India at major Chinese MedTech companies have in many cases never visited the market. Their understanding of India is built from data reports, trade show interactions, and video calls.

This matters because India is a market where on-the-ground presence changes the quality of judgment significantly. Walking hospital corridors in Delhi, sitting across from procurement directors in Mumbai, observing clinical workflows in Chennai—these experiences generate calibration that secondary research cannot replicate. The risk is not simply that companies don’t know things about India. It is that many companies don’t know what they don’t know, and make decisions based on a reflected image of the market rather than the market itself.

WExAct maintains active project operations in India with team members based locally, which is the basis for the market-level assessments in this note.

Where Chinese MedTech Has Competitive Space—and Where the Risks Are Real

Chinese medical device brands are already meaningfully present in India across several categories: ultrasound, patient monitoring, respiratory equipment, hemodialysis, and orthopedic consumables. Leading Chinese companies have established local warehouses, service centers, and training facilities in India. The market does not systematically reject Chinese products.

The competitive positioning that works in India is not primarily about price. It is about delivering a credible quality-to-cost ratio that outperforms Western brands on value while outperforming local brands on technical capability. That positioning window is real and remains open in many categories.

The risks that deserve serious attention are:

• After-sales service coverage: Indian buyers—particularly private hospital groups—have explicit service requirements and enforce them. “No one to fix it after purchase” is a documented concern about Chinese brands. Without local service infrastructure or a reliable service partner, premium product sales will stall.
• Channel management depth: Finding a national distributor is not the same as building a market. Many Chinese companies have distribution agreements in India with little visibility into downstream performance. Terminal market outcomes depend on channel system design, not distributor goodwill.
• Policy volatility: India’s import tariff structure, registration requirements, and localization mandates are subject to change. Companies need to monitor policy developments and build contingency into their market planning.
• Currency and payment risk: The rupee has a long-term depreciation trend against the dollar. Pricing models need to account for this. Public sector payment cycles can extend significantly beyond contract terms, requiring proactive cash flow planning.

A Framework for Market Entry

For companies that have decided India warrants serious evaluation, the sequencing of decisions matters.

Identify the right segment before choosing a channel

The entry logic for private hospital groups, public procurement, and tier-2 markets is sufficiently different that a single go-to-market model will not span all three. Segment fit analysis—including interviews with representative end customers and analysis of competitor performance across distribution tiers—should precede distributor selection.

Plan registration and channel strategy together

Registration ownership needs to be a deliberate strategic decision. Companies with sufficient commitment to India may find it worthwhile to establish a wholly owned local entity to hold product registrations, then authorize distributors for sales. This structure provides significantly more market control, at higher upfront investment. For companies at an earlier stage, the registration terms in distributor agreements need to be drafted carefully, including provisions for license transfer or revocation under defined conditions.

Build local service capability from the start

This does not necessarily mean a wholly owned service team. Partnering with a qualified third-party service provider, building service commitments into distributor contracts with enforcement mechanisms, and maintaining strategic spare parts inventory in key cities are all viable approaches. The right model depends on product complexity and market scale—but the absence of a local service plan is not viable for most product categories above a basic commodity level.

Plan for a multi-year investment horizon

India’s market development timeline is longer than most companies expect. The first year typically covers registration progress, relationship development, and distributor selection. Meaningful market traction begins in year two. Scalable results are a year-three-and-beyond story. Companies that enter India expecting quick returns will be disappointed. Companies that enter with a three-to-five-year investment horizon and genuine commitment to building local capability will find a market with real and durable competitive opportunity.

A Misread Market With Real Strategic Value

India’s complexity is genuine. Some of the challenges attributed to it are real; others are overstated, often by people who haven’t visited. The visa constraints of recent years have deepened the information deficit and widened the gap between how Chinese companies perceive India and what the market actually looks like on the ground.

What remains true is that India is growing, the demand is structural rather than cyclical, and Chinese MedTech companies have competitive positioning available to them that does not exist in most other markets of comparable scale. The question is not whether India can be done. It is whether a given company has the right product fit, the patience to build local capability, and the strategic discipline to design registration and channel structures correctly from the start.

For companies that can answer those questions clearly, India is not a confusing market. It is a difficult but navigable one—with a long runway for companies that arrive prepared.